Alzheimer’s blood tests in 2026 can help determine whether amyloid-related brain changes are likely in certain adults who already have cognitive symptoms, but they are not routine screening tests or stand-alone diagnoses. Accuracy depends heavily on the specific assay, the clinical setting, and whether the result is positive, negative, or indeterminate. Cost and insurance coverage vary by laboratory, health plan, billing code, location, and documentation. For example, a 68-year-old with worsening memory and objective impairment may be an appropriate candidate, while a healthy 45-year-old seeking a general “Alzheimer’s risk test” would not fit the labeled use of either FDA-cleared test. Two blood tests had received FDA clearance as Class II medical devices through the 510(k) pathway by July 25, 2026: Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio and Roche’s Elecsys Phospho-Tau (181P) Plasma.
They serve different purposes. Lumipulse is intended for symptomatic adults age 50 or older in specialized care, while Elecsys is a rule-out-oriented test for the initial primary-care assessment of symptomatic adults age 55 or older. Neither should be interpreted without a cognitive history, examination, medication review, laboratory workup, and consideration of other causes of impairment. It is also important to use precise regulatory language. These tests are FDA-cleared devices, not “FDA-approved” drugs or premarket approval devices. A study result, Breakthrough Device designation, regulatory filing, or laboratory-developed test does not carry the same meaning as FDA clearance.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Accurate Are Alzheimer’s Blood Tests in 2026?
- The Two FDA-Cleared Alzheimer’s Blood Tests Have Different Jobs
- Who Should Get an Alzheimer’s Blood Test?
- How to Ask About Cost and Insurance Coverage
- Positive, Negative, and Indeterminate Results Can All Be Misread
- When Is PET or Cerebrospinal Fluid Confirmation Still Needed?
- What to Bring to the Appointment Before Testing
- Frequently Asked Questions
How Accurate Are Alzheimer’s Blood Tests in 2026?
There is no single accuracy percentage that applies to every Alzheimer’s blood test. Results depend on the biomarker measured, the intended population, the threshold used, and what the test is compared with, usually amyloid PET imaging or cerebrospinal fluid analysis. Predictive values also change with disease prevalence: a positive result is generally more reliable in a carefully selected memory-clinic population than in a low-risk population with few or no symptoms. In the FDA-reviewed Lumipulse study, which included 499 cognitively impaired adults, 91.7% of positive results agreed with amyloid pathology identified through PET or cerebrospinal fluid testing. Among negative results, 97.3% agreed with a negative PET or cerebrospinal fluid finding. Fewer than 20% of results were indeterminate.
These figures are useful, but they describe agreement and predictive performance in a selected symptomatic population; they should not be presented as proof that the test is “more than 90% accurate” for the general public. [FDA](https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease) Roche’s Elecsys test illustrates why the type of accuracy measure matters. In FDA-reviewed primary-care data involving 312 evaluable people, only 13.1% were amyloid PET-positive. The test’s negative predictive value was 97.9%, making a negative result useful for ruling out amyloid pathology in that setting. Its positive predictive value was only 22.4%, however, and 48.7% of PET-negative participants tested positive. A positive Elecsys result therefore does not confirm Alzheimer’s disease and requires further investigation. [FDA decision summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/K252163.pdf).
The Two FDA-Cleared Alzheimer’s Blood Tests Have Different Jobs
The first FDA-cleared Alzheimer’s blood test was Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, cleared on May 16, 2025. It measures phosphorylated tau 217 and beta-amyloid 1-42 in K2-EDTA plasma and calculates a ratio on the Lumipulse G1200 laboratory system. Its labeled population is adults age 50 or older who have signs or symptoms of cognitive decline and are being evaluated in a specialized-care setting. A positive result suggests that amyloid pathology is likely; it does not, by itself, establish that Alzheimer’s disease is causing the person’s symptoms. [FDA decision summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/K242706.pdf) Roche’s Elecsys Phospho-Tau (181P) Plasma test received FDA clearance on October 8, 2025. This automated assay measures plasma p-tau181 on cobas e analyzers. It is intended for adults age 55 or older with cognitive signs, symptoms, or complaints during an initial primary-care assessment.
A negative result is consistent with a negative amyloid PET scan and can direct the clinician to investigate other causes. A positive result requires additional evaluation. The test is not recommended for patients who have already been referred to a specialist, and its use has not been established for predicting dementia or monitoring treatment. [FDA clearance letter](https://www.accessdata.fda.gov/cdrh_docs/pdf25/K252163.pdf) The distinction matters in practice. A family doctor assessing a 59-year-old with new memory complaints might use Elecsys to help decide whether amyloid pathology is unlikely. A memory specialist evaluating a 72-year-old with documented mild cognitive impairment might consider Lumipulse as part of a more advanced diagnostic pathway. Treating the two tests as interchangeable could lead to unnecessary imaging after a false-positive result or misplaced reassurance from a test used outside its intended population.
Who Should Get an Alzheimer’s Blood Test?
The strongest candidate is an adult with persistent cognitive symptoms and objective impairment who is already undergoing a structured medical evaluation. Objective impairment means that history, cognitive testing, or functional assessment shows more than an occasional forgotten name or misplaced item. Examples include repeatedly missing medication doses, becoming lost on familiar routes, struggling with finances, or showing measurable decline on cognitive testing. The 2025 Alzheimer’s Association guideline addresses people with mild cognitive impairment or dementia who are being evaluated in specialized memory care after a comprehensive clinical assessment. It does not recommend blood biomarkers as routine risk tests for cognitively unimpaired people.
A healthy 60-year-old with no measurable decline should not assume that ordering a commercial biomarker panel will provide a clear forecast of future dementia. The available tests were not cleared for that purpose. [Alzheimer’s Association guideline](https://pro.alz.org/hub/care-pathway/detection-and-diagnosis/blood-based-biomarkers-guideline) Testing may be especially relevant when confirmation of amyloid pathology would change care. That could include deciding whether PET imaging or a lumbar puncture is warranted, clarifying an uncertain diagnosis, or evaluating eligibility for an amyloid-targeting treatment. Even then, the clinician must first consider depression, sleep disorders, medication effects, thyroid disease, vitamin deficiencies, vascular injury, substance use, and other neurological conditions that can produce similar symptoms.
How to Ask About Cost and Insurance Coverage
There was no verifiable national consumer price for an Alzheimer’s blood test as of July 2026. The amount a patient owes can depend on the assay, laboratory, ordering facility, geographic location, negotiated insurer rate, billing code, deductible, coinsurance, and whether the claim meets the plan’s medical-necessity rules. A quoted laboratory price may also exclude the clinician visit, specimen processing, cognitive assessment, confirmatory imaging, or cerebrospinal fluid testing. Before having blood drawn, patients or caregivers should ask the ordering office for the exact test name, performing laboratory, billing code, estimated allowed amount, and expected out-of-pocket charge. They should then contact the insurer and ask whether prior authorization is required, whether the laboratory is in network, and what documentation is needed.
For example, a plan might process a biomarker test differently when the chart documents progressive cognitive symptoms and objective impairment than when the order is described as preventive screening. Medicare’s Clinical Laboratory Fee Schedule can list a code or payment amount without guaranteeing coverage for a particular patient. CMS explicitly warns that inclusion on the fee schedule does not itself establish that Medicare covers the service. Compared with paying cash immediately, checking coverage first takes more effort but may prevent an unexpected bill or reveal that the test must be ordered through a particular laboratory. [CMS Clinical Laboratory Fee Schedule](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/files).
Positive, Negative, and Indeterminate Results Can All Be Misread
A positive biomarker result generally means that amyloid-related pathology is more likely, not that the person definitively has Alzheimer’s dementia. Amyloid pathology can exist before dementia develops, and cognitive symptoms may have multiple causes. With the Elecsys test, the low positive predictive value in the FDA-reviewed primary-care population makes this warning particularly important: most positive results in that study did not correspond to a positive amyloid PET scan. A negative result can be more useful when a test was designed and validated as a rule-out tool. For an appropriate primary-care patient, a negative Elecsys result may shift attention toward sleep apnea, depression, medication side effects, vascular disease, or another neurological disorder.
It does not mean that the cognitive complaint is imaginary or that no further evaluation is needed. It means the tested pattern is consistent with a negative amyloid PET result under the conditions of the test’s labeled use. Lumipulse can also return an indeterminate result. In its FDA-reviewed study, fewer than 20% of results fell into that category. An indeterminate result is not a weak positive or a diagnosis in progress; it means the result does not reliably classify amyloid status using the assay’s designated thresholds. Repeating the same test without addressing timing, handling, clinical context, or the need for PET or cerebrospinal fluid confirmation may simply reproduce uncertainty.
When Is PET or Cerebrospinal Fluid Confirmation Still Needed?
The Alzheimer’s Association guideline separates blood tests used for triage from those capable of substituting for amyloid PET or cerebrospinal fluid testing. A triage test should have greater than 90% sensitivity and greater than 75% specificity: a negative result can rule out amyloid pathology with high probability, but a positive result should be confirmed with PET or cerebrospinal fluid analysis. To substitute for those established tests, a blood biomarker must exceed both 90% sensitivity and 90% specificity.
The guideline cautions that many commercially available tests do not meet these thresholds. For example, if a symptomatic memory-clinic patient has a positive triage blood test and treatment eligibility depends on documented amyloid pathology, the clinician may still order an amyloid PET scan or lumbar puncture. PET is noninvasive but may be expensive or difficult to access; cerebrospinal fluid testing avoids radiation but requires a lumbar puncture. The blood test can narrow the pathway without automatically replacing either procedure.
What to Bring to the Appointment Before Testing
A useful pretest appointment includes more than a request for a biomarker order. Bring a medication and supplement list, a timeline of cognitive changes, examples of affected daily activities, relevant medical records, and—when possible—a family member or other person who has observed the changes. Ask which assay will be used, why it fits the clinical setting, how positive and indeterminate results will be handled, and whether confirmatory testing would change diagnosis or treatment.
A patient taking a sedating sleep medication, for example, may discover during the evaluation that symptoms began after a dose increase. Another patient may show progressive impairment despite correcting thyroid dysfunction. Those two situations call for different diagnostic pathways, even if both patients initially arrived asking for an “Alzheimer’s blood test.”.
Frequently Asked Questions
Can an Alzheimer’s blood test diagnose Alzheimer’s disease by itself?
No. The FDA-cleared tests are aids to evaluation. They assess biomarkers associated with amyloid pathology, which must be interpreted alongside symptoms, cognitive testing, medical history, examination, and sometimes PET imaging or cerebrospinal fluid analysis.
Should someone without memory symptoms get tested?
Routine testing of cognitively unimpaired people is not supported by the labeled indications or the 2025 Alzheimer’s Association specialized-care guideline. The FDA-cleared tests were not established as general screening tools or as predictors of who will develop dementia.
Does a positive Elecsys p-tau181 result mean a person has Alzheimer’s?
No. In the FDA-reviewed primary-care study, the positive predictive value was 22.4%, and 48.7% of amyloid PET-negative participants tested positive. A positive result requires further investigation.
Is a blood test cheaper than an amyloid PET scan or lumbar puncture?
The blood draw may be less burdensome, but no single national consumer price can be verified. Total costs depend on the laboratory, insurer, clinical visits, confirmatory testing, and the patient’s deductible and coinsurance.
Will Medicare or private insurance pay for the test?
Coverage varies by payer, plan, billing code, location, and medical-necessity documentation. A code or payment amount appearing on Medicare’s Clinical Laboratory Fee Schedule does not by itself guarantee coverage.
